


## CLAIMS

## 1. A compound of formula



5 wherein

m is 0, 1, 2, 3 or 4;

each R<sup>1</sup> independently represents halogen, cyano, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy or sulphonamido;X represents a bond, -CH<sub>2</sub>- or -O-, Y represents a bond, -CH<sub>2</sub>- or -O-, and Z represents a bond, -O-, -NH- or -CH<sub>2</sub>-, provided that only one of X, Y and Z can represent a bond at any one time and provided that X and Y do not both simultaneously represent -O-;

n is 0, 1 or 2;

each R<sup>2</sup> independently represents halogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

15 q is 0 or 1;

t is 0, 1, 2, 3, 4 or 5;

each R<sup>3</sup> independently represents halogen, cyano, nitro, hydroxyl, -C(O)H, -NR<sup>9</sup>R<sup>10</sup>, -CH<sub>2</sub>C(O)NR<sup>11</sup>R<sup>12</sup>, -CH<sub>2</sub>NHC(O)R<sup>13</sup>, -NHSO<sub>2</sub>R<sup>14</sup>, -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, -CH<sub>2</sub>-R<sup>17</sup>, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, phenylcarbonyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, phenyl and a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent selected from halogen, cyano, hydroxyl, carboxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy and C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl;

$R^4, R^5, R^6, R^7$  and  $R^8$  each independently represent hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

$R^9$  and  $R^{10}$  each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

$R^{11}$  and  $R^{12}$  each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, or  $R^{11}$  and  $R^{12}$

- 5 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

$R^{13}$  and  $R^{14}$  each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl; and

$R^{15}$  and  $R^{16}$  each independently represent hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, or  $R^{15}$  and  $R^{16}$

- 10 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from hydroxyl;

$R^{17}$  is a 5 to 7 membered saturated heterocyclic ring containing at least one nitrogen atom, which ring may be optionally substituted with one or more oxo groups;

- 15 or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein X and Y have the meanings shown in the following table:

X	Y
bond	O
O	bond
CH <sub>2</sub>	bond
bond	CH <sub>2</sub>

- 20 3. A compound according to claim 1 or claim 2, wherein Z represents -O- or -CH<sub>2</sub>-.
4. A compound according to any one of claims 1 to 3, wherein q is 1.

5. A compound according to any one of claims 1 to 4, wherein m is 1 and R<sup>1</sup> represents halogen.

6. A compound according to any one of claims 1 to 5, wherein each R<sup>3</sup> independently

represents halogen, cyano, nitro, hydroxyl, -C(O)H, -NR<sup>9</sup>R<sup>10</sup>, -CH<sub>2</sub>C(O)NR<sup>11</sup>R<sup>12</sup>,  
-CH<sub>2</sub>NHC(O)R<sup>13</sup>, -NHSO<sub>2</sub>R<sup>14</sup>, -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, -CH<sub>2</sub>-R<sup>17</sup>, C<sub>1</sub>-C<sub>4</sub> alkylcarbonyl,  
phenylcarbonyl, C<sub>5</sub>-C<sub>6</sub> cycloalkyl or a group selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl,  
C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, phenyl and a saturated or unsaturated 5- to 6-membered  
heterocyclic ring system comprising one, two, three or four ring heteroatoms  
independently selected from nitrogen, oxygen and sulphur, each group being optionally  
substituted with one, two, three or four substituents independently selected from halogen,  
cyano, hydroxyl, carboxyl, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> alkoxy carbonyl.

7. A compound according to claim 6, wherein the saturated or unsaturated 5- to 6-  
membered heterocyclic ring system is isoxazolyl, pyrrolyl, morpholinyl, piperidinyl or  
oxadiazolyl.

8. A compound according to claim 1 selected from:

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-  
methoxyphenoxy)propan-2-ol hydrochloride,

2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-  
hydroxypropyl]oxy}phenol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(2-  
hydroxyethoxy)phenoxy]propan-2-ol hydrochloride,

2-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-  
hydroxypropyl]oxy}phenyl)-N-methylacetamide trifluoroacetate (salt),

(3S)-1-[(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-  
hydroxypropyl]oxy}phenyl)acetyl]pyrrolidin-3-ol,

N-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-  
hydroxypropyl]oxy}benzyl)acetamide,

- 2-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)-N-methylacetamide,
- 2-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)-N-methylacetamide trifluoroacetate (salt),
- 5 2-(4-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-2-methoxyphenyl)-N-methylacetamide,
- (2S)-1-(2-Amino-5-methoxyphenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol bis(trifluoroacetate),
- N-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)methanesulfonamide trifluoroacetate,
- 10 N-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)methanesulfonamide trifluoroacetate,
- (2S)-1-(4-Bromo-2-fluorophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 15 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(3-ethynylphenoxy)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,4-dichloro-3,5-dimethylphenoxy)propan-2-ol,
- (2S)-1-(4-Chloro-2-isoxazol-5-ylphenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 20 (4-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}phenyl)(phenyl)methanone,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,3,4,6-tetrachlorophenoxy)propan-2-ol,
- 25 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-cyclohexyl-5-methylphenoxy)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-phenoxypropan-2-ol,
- (2S)-1-(2-Bromophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 30 (2S)-1-(2-Bromophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,

- 2-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzaldehyde,
- 5-tert-Butyl-2-{{(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzaldehyde,
- 5 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(1,1':3',1"-terphenyl-2'-yloxy)propan-2-ol,
- 10 1-(2-{{(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-5-methoxyphenyl)ethanone,
- 1-(5-Bromo-2-{{(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}phenyl)ethanone,
- 15 (2S)-1-(4-Chloro-2-isopropyl-5-methylphenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,3-dimethyl-4-nitrophenoxy)propan-2-ol,
- 15 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,4-dichlorophenoxy)propan-2-ol,
- Ethyl (2E)-3-(4-{{(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-3-methoxyphenyl)acrylate,
- 20 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-methyl-3-nitrophenoxy)propan-2-ol,
- 5-Chloro-2-{{(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzaldehyde,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-fluorophenoxy)propan-2-ol,
- 25 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(3-fluorophenoxy)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(4-fluorophenoxy)propan-2-ol,
- (2S)-1-(2-Chlorophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 30

- (2S)-1-(3-Chlorophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- (2S)-1-(4-Chlorophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 5 (2S)-1-(3-Bromophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- (2S)-1-(4-Bromophenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- 10 (2S)-1-(2-tert-Butyl-5-methylphenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(trifluoromethyl)phenoxy]propan-2-ol,
- 15 1-(2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4,5-dimethoxyphenyl)ethanone,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy]propan-2-ol,
- 20 (2S)-1-(4-Chloro-3-ethylphenoxy)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[3-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy]propan-2-ol,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(hydroxymethyl)phenoxy]propan-2-ol,
- 25 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(hydroxyethyl)phenoxy]propan-2-ol,
- 3-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzonitrile,
- 2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzonitrile,
- (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-morpholin-4-
- 30 ylphenoxy)propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,3-difluoro-6-nitrophenoxy)propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,3,6-trichlorophenoxy)propan-2-ol,

5 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(4-fluoro-2-methoxyphenoxy)propan-2-ol,

5-Chloro-2-[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-3-methylbenzaldehyde,

10 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[4-(4-methylpiperidin-1-yl)-2-nitrophenoxy]propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2,4-dichloro-3,5-dimethyl-6-nitrophenoxy)propan-2-ol,

15 1-(3,5-Dichloro-2-[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}phenyl)propan-1-one,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(4-ethylphenoxy)propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-ethylphenoxy)propan-2-ol,

20 (2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(3-ethylphenoxy)propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(3-morpholin-4-ylphenoxy)propan-2-ol,

(2S)-1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]propan-2-ol,

25 4-[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}benzonitrile,

(2S)-1-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[2-(pyrrolidin-1-ylsulfonyl)phenoxy]propan-2-ol.

30 1-(2-[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropoxy]benzyl}imidazoline-2,4-dione,


(2S)-{2-chloro-5-[3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropoxy]phenoxy}acetic acid,

(2S)-{2,4-dichloro-5-[3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropoxy]phenoxy}acetic acid,

and pharmaceutically acceptable salts and solvates of any one thereof.


9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

(a) reacting a compound of formula




10

wherein m, R<sup>1</sup>, n, R<sup>2</sup>, q, X, Y and Z are as defined in formula (I), with a compound of formula




wherein t, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are as defined in formula (I); or


15 (b) reacting a compound of formula




wherein m, R<sup>1</sup>, n, R<sup>2</sup>, q, X, Y, Z, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are as defined in formula (I), with a compound of formula



wherein t and R<sup>3</sup> are as defined in formula (I), in the presence of a suitable base; or  
(c) when t is at least one and a group R<sup>3</sup> represents -NHSO<sub>2</sub>R<sup>14</sup>, reacting a compound of formula




wherein t' is 0, 1, 2, 3 or 4, R<sup>3'</sup> is as defined for R<sup>3</sup> in formula (I) other than -NHSO<sub>2</sub>R<sup>14</sup> and m, R<sup>1</sup>, n, R<sup>2</sup>, q, X, Y, Z, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are as defined in formula (I), with a compound of formula



wherein L<sup>1</sup> represents a leaving group and R<sup>14</sup> is as defined in formula (I), in the presence of a suitable base;

(d) where t is at least 1 and a group R<sup>3</sup> represents -CH<sub>2</sub>-R17, where R17 is a 5 to 7-membered saturated heterocyclic ring containing 2 nitrogen atoms and which ring is substituted by two oxo groups, reacting a compound of formula

15



wherein t' is 0, 1, 2, 3 or 4,  $R^{3'}$  is as defined for  $R^3$  in formula (I) other than  $-CH_2-R17$ , and m,  $R^1$ , n,  $R^2$ , q, X, Y, Z,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are as defined in formula (I), with an alkyl glycinate in the presence of a reducing agent, and subsequently with metal isocyanate;

and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound of formula (I) or a pharmaceutically-acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 for use in therapy.
- 20 13. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating rheumatoid arthritis.

5     15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.

10    16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating asthma.

15    17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating multiple sclerosis.

18. A method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

20

19. A method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

25

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**